Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

A survey of school's preparedness for managing anaphylaxis in pupils with food allergy.

Raptis G, Perez-Botella M, Totterdell R, Gerasimidis K, Michaelis LJ.

Eur J Pediatr. 2020 Apr 5. doi: 10.1007/s00431-020-03645-0. [Epub ahead of print]

PMID:
32249360
2.

Discovery and expression analysis of novel transcripts of the human SR-related CTD-associated factor 1 (SCAF1) gene in human cancer cells using Next-Generation Sequencing.

Adamopoulos PG, Raptis GD, Kontos CK, Scorilas A.

Gene. 2018 Sep 5;670:155-165. doi: 10.1016/j.gene.2018.05.044. Epub 2018 May 19.

PMID:
29787824
3.

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D.

NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016.

4.

Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.

Andreopoulou E, Vigoda IS, Valero V, Hershman DL, Raptis G, Vahdat LT, Han HS, Wright JJ, Pellegrino CM, Cristofanilli M, Alvarez RH, Fehn K, Fineberg S, Sparano JA.

Breast Cancer Res Treat. 2013 Oct;141(3):429-35. doi: 10.1007/s10549-013-2704-x. Epub 2013 Sep 26.

5.

DES thrombosis related to antiplatelet therapy noncompliance: a consequence of the Greek financial crisis.

Davlouros P, Gizas V, Stavrou K, Raptis G, Alexopoulos D.

Int J Cardiol. 2013 Oct;168(4):4497-9. doi: 10.1016/j.ijcard.2013.06.121. Epub 2013 Jul 25. No abstract available.

PMID:
23890972
6.

Platelet inhibition by IV glyceryl trinitrate in patients with stable coronary artery disease on dual antiplatelet therapy subjected to PCI.

Davlouros P, Mavronasiou E, Damelou A, Xanthopoulou I, Gizas V, Raptis G, Hahalis G, Alexopoulos D.

Int J Cardiol. 2013 Oct 3;168(3):3069-70. doi: 10.1016/j.ijcard.2013.04.092. Epub 2013 Apr 30. No abstract available.

PMID:
23642613
7.

Cord blood leptin levels of healthy neonates are associated with IFN-γ production by cord blood T-cells.

Mouzaki A, Panagoulias I, Raptis G, Farri-Kostopoulou E.

PLoS One. 2012;7(7):e40830. doi: 10.1371/journal.pone.0040830. Epub 2012 Jul 16.

8.

Look again: the importance of second opinions in breast pathology.

Bleiweiss IJ, Raptis G.

J Clin Oncol. 2012 Jun 20;30(18):2175-6. doi: 10.1200/JCO.2012.42.1255. Epub 2012 May 7. No abstract available.

PMID:
22564991
9.

Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.

Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, Raptis G, Desnick RJ.

Clin Pharmacol Ther. 2011 Oct;90(4):605-11. doi: 10.1038/clpt.2011.153. Epub 2011 Sep 7.

PMID:
21900890
10.

Hormonal modulation in the treatment of breast cancer.

Adelson K, Germain D, Raptis G, Biran N.

Endocrinol Metab Clin North Am. 2011 Sep;40(3):519-32, viii. doi: 10.1016/j.ecl.2011.05.011. Review.

PMID:
21889718
11.

Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry.

Jaremko M, Kasai Y, Barginear MF, Raptis G, Desnick RJ, Yu C.

Anal Chem. 2010 Dec 15;82(24):10186-93. doi: 10.1021/ac102337d. Epub 2010 Nov 18.

PMID:
21086978
12.

Highlights of the Chemotherapy Foundation Symposium XXVII: therapeutic options for breast cancer.

Barginear MF, Raptis G.

Expert Rev Anticancer Ther. 2010 Feb;10(2):149-51. doi: 10.1586/era.09.174.

PMID:
20131991
13.

Conducting Molecular Epidemiological Research in the Age of HIPAA: A Multi-Institutional Case-Control Study of Breast Cancer in African-American and European-American Women.

Ambrosone CB, Ciupak GL, Bandera EV, Jandorf L, Bovbjerg DH, Zirpoli G, Pawlish K, Godbold J, Furberg H, Fatone A, Valdimarsdottir H, Yao S, Li Y, Hwang H, Davis W, Roberts M, Sucheston L, Demissie K, Amend KL, Tartter P, Reilly J, Pace BW, Rohan T, Sparano J, Raptis G, Castaldi M, Estabrook A, Feldman S, Weltz C, Kemeny M.

J Oncol. 2009;2009:871250. doi: 10.1155/2009/871250. Epub 2009 Oct 25.

14.

Spontaneous internal carotid artery dissection: an uncommon cause of recurrent postpartum headache.

Stamboulis E, Raptis G, Andrikopoulou A, Arvaniti C, Brountzos E, Oikonomopoulos N, Stefanis L, Voumvourakis K.

J Neuroimaging. 2011 Jan;21(1):76-8. doi: 10.1111/j.1552-6569.2009.00387.x.

PMID:
19453826
15.

Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.

Crew KD, Capodice JL, Greenlee H, Apollo A, Jacobson JS, Raptis G, Blozie K, Sierra A, Hershman DL.

J Cancer Surviv. 2007 Dec;1(4):283-91. doi: 10.1007/s11764-007-0034-x. Epub 2007 Oct 12.

PMID:
18648963
16.

Effect of pretreatment distress on daily fatigue after chemotherapy for breast cancer.

Higgins SC, Montgomery GH, Raptis G, Bovbjerg DH.

J Oncol Pract. 2008 Mar;4(2):59-63. doi: 10.1200/JOP.0822002.

17.

Translation, please.

Bleiweiss IJ, Raptis G.

Lancet Oncol. 2007 Dec;8(12):1044-1045. doi: 10.1016/S1470-2045(07)70349-2. No abstract available.

PMID:
18054869
18.

Pulmonary involvement in patients with early rheumatoid arthritis.

Metafratzi ZM, Georgiadis AN, Ioannidou CV, Alamanos Y, Vassiliou MP, Zikou AK, Raptis G, Drosos AA, Efremidis SC.

Scand J Rheumatol. 2007 Sep-Oct;36(5):338-44.

PMID:
17963162
19.

Tumor size is of prognostic value in surgically treated FIGO stage II cervical cancer.

Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B.

Gynecol Oncol. 2007 Nov;107(2):310-5. Epub 2007 Sep 12.

PMID:
17826822
20.

Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.

Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL.

J Clin Oncol. 2007 Sep 1;25(25):3877-83.

PMID:
17761973
21.

Racial disparities in treatment and survival of male breast cancer.

Crew KD, Neugut AI, Wang X, Jacobson JS, Grann VR, Raptis G, Hershman DL.

J Clin Oncol. 2007 Mar 20;25(9):1089-98.

PMID:
17369572
22.

Pattern of invasion is of prognostic value in surgically treated cervical cancer patients.

Horn LC, Fischer U, Raptis G, Bilek K, Hentschel B, Richter CE, Braumann UD, Einenkel J.

Gynecol Oncol. 2006 Dec;103(3):906-11. Epub 2006 Jul 28.

PMID:
16876852
23.

Identification of mammaglobin as a novel serum marker for breast cancer.

Bernstein JL, Godbold JH, Raptis G, Watson MA, Levinson B, Aaronson SA, Fleming TP.

Clin Cancer Res. 2005 Sep 15;11(18):6528-35.

24.
25.

CD44-v6 concentrations in carcinoma of the uterine cervix: lack of prognostic significance.

Horn LC, Raptis G, Fischer U, Hentschel B, Köhler U, Richter CE, Martin R.

Arch Gynecol Obstet. 2005 Dec;273(2):104-6. Epub 2005 Jul 11.

PMID:
16007507
26.

Clinical relevance of urokinase-type plasminogen activator and its inhibitor type 1 (PAI-1) in squamous cell carcinoma of the uterine cervix.

Horn LC, Pippig S, Raptis G, Fischer U, Köhler U, Hentschel B, Martin R.

Aust N Z J Obstet Gynaecol. 2002 Oct;42(4):383-6.

PMID:
12403286
27.

Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer.

Paciucci PA, Raptis G, Bleiweiss I, Weltz C, Lehrer D, Gurry R.

Anticancer Drugs. 2002 Sep;13(8):791-5.

PMID:
12394262
28.

DNA cytometric analysis of surgically treated squamous cell cancer of the uterine cervix, stage pT1b1-pT2b.

Horn LC, Raptis G, Nenning H.

Anal Quant Cytol Histol. 2002 Feb;24(1):23-9.

PMID:
11865946
29.

Familial cancer history in patients with carcinoma of the cervix uteri.

Horn LC, Raptis G, Fischer U.

Eur J Obstet Gynecol Reprod Biol. 2002 Feb 10;101(1):54-7.

PMID:
11803100
30.

p53 in surgically treated and pathologically staged cervical cancer: correlation with local tumor progression, but not with lymphatic spread.

Horn LC, Fischer U, Hänel C, Kuhn H, Raptis G, Bilek K.

Pathol Res Pract. 2001;197(9):605-9.

PMID:
11569924
31.

[Significance of family anamnesis in cervix carcinoma].

Fischer U, Raptis G, Horn LC.

Zentralbl Gynakol. 2001 May;123(5):302-7. German.

PMID:
11449624
32.

[Epidemiology and pathogenesis of cervical cancer].

Fischer U, Raptis G, Gessner W, Roschlau U, Dressel K, Bilek K, Horn LC.

Zentralbl Gynakol. 2001 Apr;123(4):198-205. Review. German.

PMID:
11370527
33.

A pilot study of interpersonal psychotherapy by telephone with cancer patients and their partners.

Donnelly JM, Kornblith AB, Fleishman S, Zuckerman E, Raptis G, Hudis CA, Hamilton N, Payne D, Massie MJ, Norton L, Holland JC.

Psychooncology. 2000 Jan-Feb;9(1):44-56.

PMID:
10668059
34.

5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study.

Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L.

J Clin Oncol. 1999 Apr;17(4):1118.

PMID:
10561169
35.

Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy.

Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L.

J Clin Oncol. 1999 Jan;17(1):93-100.

PMID:
10458222
36.

Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.

D'Andrea G, Fennelly D, Norton L, Baselga J, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD.

Clin Cancer Res. 1999 Feb;5(2):275-9.

37.

Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.

Hudis C, Riccio L, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Lebwohl D, Moynahan M, Raptis G, Surbone A, Sklarin N, Yao TJ, Keefe D, Norton L.

Cancer Invest. 1998;16(2):67-71. No abstract available.

PMID:
9512671
38.

Phase II study of semisynthetic paclitaxel in metastatic breast cancer.

Hudis C, Riccio L, Holmes F, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Moynahan M, Raptis G, Sklarin N, Surbone A, Uhlenhopp M, Maickel N, Yao TJ, Hellmann S, Usakewicz J, Hortobagyi G, Norton L.

Eur J Cancer. 1997 Nov;33(13):2198-202.

PMID:
9470806
39.

Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience.

Seidman AD, Hudis CA, Raptis G, Baselga J, Fennelly D, Norton L.

Oncology (Williston Park). 1997 Mar;11(3 Suppl 2):20-8. Review.

40.

Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus.

Luzi L, Hering BJ, Socci C, Raptis G, Battezzati A, Terruzzi I, Falqui L, Brandhorst H, Brandhorst D, Regalia E, Brambilla E, Secchi A, Perseghin G, Maffi P, Bianchi E, Mazzaferro V, Gennari L, Di Carlo V, Federlin K, Pozza G, Bretzel RG.

J Clin Invest. 1996 Jun 1;97(11):2611-8.

41.

Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.

Hudis C, Seidman A, Raptis G, Fennelly D, Gilewski T, Baselga J, Theodoulou M, Sklarin N, Moynahan M, Surbone A, Currie V, Lebwohl D, Uhlenhopp M, Crown J, Norton L.

Semin Oncol. 1996 Feb;23(1 Suppl 1):58-64.

PMID:
8629040
42.

Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia.

Kritz AD, Raptis G, Menendez-Botet C, Maslak P, Jakubowski A.

Am J Hematol. 1996 Feb;51(2):117-21.

43.

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.

Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, Baselga J, Raptis G, Gollub M, Robles M, Bruno R, Norton L.

J Clin Oncol. 1996 Jan;14(1):58-65.

PMID:
8558221
44.

High-dose chemotherapy of breast cancer.

Crown J, Raptis G, Hamilton N, Hudis C, Vahclat L, Fennelly D, Norton L.

Can J Oncol. 1995 Dec;5 Suppl 1:80-2. Review.

PMID:
8853530
45.

Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.

Hudis CA, Seidman AD, Baselga J, Raptis G, Lebwohl D, Gilewski T, Currie V, Moynahan ME, Sklarin N, Fennelly D, et al.

Semin Oncol. 1995 Dec;22(6 Suppl 15):18-23.

PMID:
8643965
46.

Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer.

Vahdat L, Raptis G, Fennelly D, Hamilton N, Reich L, Tiersten A, Harrison M, Hudis C, Moore M, Yao TJ, et al.

Clin Cancer Res. 1995 Nov;1(11):1267-73.

47.

Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer.

Seidman AD, Hudis CA, Fennelly D, Raptis G, Baselga J, Norton L.

Semin Oncol. 1995 Oct;22(5 Suppl 12):108-16. Review.

PMID:
7481852
48.

Natural course of insulin sensitivity and insulin reserve in early insulin-dependent diabetes mellitus.

Linn T, Ebener K, Raptis G, Laube H, Federlin K.

Metabolism. 1995 May;44(5):617-23.

PMID:
7752910
49.

Carboplatin and etoposide in metastatic breast cancer.

Crown J, Hamilton N, Raptis G, Kritz A, Vahdat L, Norton L.

Ann Oncol. 1995 Apr;6(4):403. No abstract available.

50.

High-dose chemotherapy of breast cancer: current status and developmental strategies.

Crown J, Raptis G, Hamilton N, Fennelly D, Vahdat L, Norton L.

Eur J Cancer. 1995;31A(5):809-11. No abstract available.

PMID:
7640062

Supplemental Content

Loading ...
Support Center